Parexel, a provider of solutions to accelerate development and delivery of innovative therapies, from clinical through commercialisation, and NeoGenomics, a provider of cancer-focused genetic testing services and global oncology contract research services, announced a partnership to advance the application of precision medicine in oncology clinical trials by applying real-world genomics data to accelerate patient matching and optimise trial design, site selection, clinical development and translational research.
“The collaboration with NeoGenomics will enhance Parexel’s use of real-world data across various applications, including identifying and estimating prevalence of genomic mutations within respective populations, genomic patterning to stratify patients according to novel biomarkers, and use of de-identified patient data to precisely target patient populations. Collectively these data are designed to better inform clinical trial feasibility, enhance patient matching and create a holistic view of the patient journey by linking genomic data with clinical and consumer datasets. The collaboration will ultimately enable researchers to quickly enrol patients with common to rare cancer mutations and connect them to clinical trials providing the best likelihood of potential treatment success,” informed the companies through a statement.
“Parexel’s partnership with NeoGenomics provides access to greater predictive modelling capabilities so that we can rapidly identify specific patients and connect them to clinical trials that provide them with the best potential for treatment, advance our understanding of their disease and identify the drug’s effects and potential benefits. This collaboration supports our efforts to adopt more novel approaches in the identification of data populations for oncology studies while keeping the patient at the centre of everything we do,” Sy Pretorius, MD, President, Clinical Development and Chief Medical Officer at Parexel.
“We are thrilled to collaborate with Parexel to provide our robust genomic and clinical database to help match cancer patients to clinical trials and therapies that are precisely targeted to their unique tumour types and genomic biomarkers. We look forward to our strategic partnership and future opportunities to broaden our relationship based on customer needs in the oncology space,” said Douglas VanOort, NeoGenomics’ Chairman and CEO.
“The strategic partnership between Parexel and NeoGenomics will enable biopharma customers to make evidence-based decisions regarding trial designs, companion diagnostics and drug repurposing as well as to build external control arms using genomic data, ultimately providing cancer patients access to the most effective therapies when and where they need them. The companies are considering potential opportunities to expand the scope of the partnership, including lab services and biomarker capabilities,” said the statement.